Susanne Herz

Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.

Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.

Treating recurrent tuboovarian carcinoma with multiple lines of bevacizumab-based therapy: Feasibility and effectiveness in the clinical routine.

Sensor-controlled scalp cooling for chemotherapy-induced alopecia: Safety and effectiveness in primary breast cancer patients exposed to anthracyclines and/or taxanes in the neoadjuvant or adjuvant setting.

Direct effects on bone metabolism induced by perioperative anthracycline- and/or taxane-based chemotherapy depend on the menopausal status of patients with primary breast cancer.

Bevacizumab-based therapy in patients with heavily pretreated ovarian and other Mullerian tract cancers.

Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.

Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in women treated for either breast or female genital tract cancer: A German experience using the Paxman system.

Incidence of abnormal HER2 values in the serum of breast cancer patients: influence of disease stage and HER2 status.

PO141 SUCCESSFUL USE OF HER2 TARGETED AGENTS IN PATIENTS WITH HEAVILY PRETREATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTING WITH ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN AND/OR HER2 OVEREXPRESSING CIRCULATING TUMOR CELLS